Biogen Inc (BIIB)

pos +7.60
Today's Range: 284.66 - 291.63 | BIIB Avg Daily Volume: 1,619,800
Last Update: 05/31/16 - 12:38 PM EDT
Volume: 904,226
YTD Performance: -7.69%
Open: $285.15
Previous Close: $282.79
52 Week Range: $242.07 - $420.99
Oustanding Shares: 219,051,491
Market Cap: 61,945,571,140
6-Month Chart
TheStreet Ratings Grade for BIIB
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 9 10 10 10
Moderate Buy 2 2 2 2
Hold 6 8 8 8
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.79 1.88 1.88 1.88
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 18.48
Price Earnings Comparisons:
BIIB Sector Avg. S&P 500
18.48 17.40 12.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
6.92% -29.81% 20.21%
Revenue 10.80 0.90 0.25
Net Income 22.20 1.60 0.37
EPS 24.00 1.60 0.38
Earnings for BIIB:
Revenue 9.42B
Average Earnings Estimates
Qtr (06/16) Qtr (09/16) FY (12/16) FY (12/17)
Average Estimate $4.67 $4.74 $18.96 $20.20
Number of Analysts 20 20 20 20
High Estimate $5.29 $5.33 $20.80 $22.70
Low Estimate $4.41 $4.49 $18.40 $18.89
Prior Year $4.22 $4.48 $17.01 $18.96
Growth Rate (Year over Year) 10.68% 5.78% 11.49% 6.53%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands

Biogen Is Looking Quite Strong Real Money Pro($)

There is a fresh buy signal on the chart.
The essence of sloppiness is to let it all ride, so look at your portfolio and decide what has moved too much and what you should take off.
I prefer a bullish synthetic call.
It is hard to see much growth in the market overall, until earnings growth returns.
After an asset price drop, large pharmaceutical companies are looking for strategic purchases.
BIIB could be headed above $300 over the intermediate term.

Some Stocks Are Really Cheap Real Money Pro($)

There are lots of winners in the first quarter.
Apr 22, 2016 | 7:25 AM EDT
Shares of BIIB now seen reaching $319, according to Leerink Partners. Estimates also reduced, as the MS franchise is facing pressure. M...
Candidates have decried rising drug and medical prices, but there are reasons to like these stocks.
With Pfizer deal dead, Allergan is ready to go shopping.

Columnist Conversations

Market flat as we hit the noon hour. Oil tries once again to scale the $50 level. Biotech goes for three wee...
I would think he sees the boatload of cash coming to AGN if/when they close the TEVA deal for their generics. ...
Looking like a slightly up start to the holiday shortened trading week as consumer spending posts its best gai...
Put politics aside and the April Personal Consumption and Personal Spending data look pretty scary. In current...


News Breaks

Powered by


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.